Cirrhosis is a condition in which the liver slowly deteriorates and malfunctions due to chronic injury. Scar tissue replaces healthy liver tissue, partially blocking the flow of blood through the liver. Scarring also impairs the liver’s ability to control infections, remove bacteria and toxins from the blood, process nutrients, hormones and drugs, make proteins that regulate blood clotting and produce bile to help absorb fats—including cholesterol—and fat-soluble vitamins.
Excessive consumption of fructose -; a sweetener ubiquitous in the American diet -; can result in non-alcoholic fatty liver disease (NAFLD), which is comparably abundant in the United States.
Non-alcoholic fatty liver disease is the most common chronic liver disease in the world, with sometimes life-threatening consequences.
Infections in humans caused by the hepatitis B virus (HBV) represent a major public health problem. Despite the availability of effective protective vaccines, more than 250 million individuals worldwide are chronically infected according to WHO estimates.
Diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) are all common diseases that can lead to serious health implications.
Mesenchymal stem cells, or MSCs, have the ability to differentiate into an array of different types of cells, such as fat, bone, and muscle cells.
For the first time, researchers at The Westmead Institute for Medical Research have identified and described a new and unique subset of human cells that are involved in the immune response against hepatitis B (HBV) infection. The discovery could help develop new treatments for HBV and inform future vaccine design.
Liver cancer is one of the deadliest cancers. It is insidious and does not present symptoms until it has progressed considerably, at which point, treatment options are limited and chances of survival are low. The most common type of liver cancer is hepatocellular carcinoma.